beta-amyloid 42 (Aβ42) antibody and antigen (Recombinant protein)
Diagnostic beta-amyloid 42 (Aβ42) antibodies (anti-beta-amyloid 42, anti-Aβ42) and antigens (recombinant beta-amyloid 42 (Aβ42) protein) for Neurodegenerative diseases Aβ42 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-h-Aβ42-Ag01 | Recombinant human APP/Aβ42/A4/AD1 Protein | 3090 |
GMP-h-Aβ42-Ab01 | Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb) | 3090 |
GMP-h-Aβ42-Ab02 | Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb) | 3090 |
GMP-h-Aβ42-Ab03 | Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb) | 3090 |
GMP-h-Aβ42-Ab04 | Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb) | 3090 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-h-Aβ42-Ag01 |
Product Name | Recombinant human APP/Aβ42/A4/AD1 Protein |
Target/Biomarker | beta-amyloid 42 (Aβ42) |
Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4 |
Expression platform | synthesized |
Isotypes | NA |
Bioactivity validation | beta-amyloid 42 (Aβ42) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease (AD),Parkinson's disease(PD)) and related syndrome evaluation. |
Products description | Recombinant human APP/Aβ42/A4/AD1 Protein was expressed in synthesized expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | positive control,ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-h-Aβ42-Ab01, GMP-h-Aβ42-Ab02 |
Product Name | Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb) |
Target/Biomarker | beta-amyloid 42 (Aβ42) |
Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4 |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Human beta-amyloid 42 (Aβ42) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other beta-amyloid 42 (Aβ42) antibodies in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease (AD),Parkinson's disease(PD)) and related syndrome evaluation. |
Tag | mFc |
Products description | Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-h-Aβ42-Ab03, GMP-h-Aβ42-Ab04 |
Product Name | Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb) |
Target/Biomarker | beta-amyloid 42 (Aβ42) |
Alias of Target/Biomarker | AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4 |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Human beta-amyloid 42 (Aβ42) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other beta-amyloid 42 (Aβ42) antibodies in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease (AD),Parkinson's disease(PD)) and related syndrome evaluation. |
Tag | hFc |
Products description | Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Figure 1. ELISA Validation of GeneMedi's Aβ40/Aβ42 antibody
Indirect ELISA analysis of clone [B], [A] and [A] antibody specificity, [B] and [A] can Recognizes Aβ40, while [A] has no cross-reactivity with Aβ40 Picture indirect ELISA analysis of cloned [B], [A] and [A] antibody specificity. [B] and [A] can recognize Aβ42 , while [A] has no cross-reaction with Aβ42.
A: GMP-h-Aβ42-Ab01
B: GMP-h-Aβ42-Ab02
The high-performance Aβ40 and Aβ42 antibody raw materials developed by
GeneMedi have the advantages of good specificity and high sensitivity, and are the preferred raw materials for the development of in vitro diagnostics reagents for Alzheimer's disease.
Figure 2. CLIA verification data of GeneMedi's Aβ40/Aβ42 antibody
Beta-amyloid(1-42) antibodies (GMP-h-Aβ42-Ab02 and GMP-h-Aβ42-Ab01) established a standard curve by chemiluminescence method, and the detection range of Aβ42 was 100-1700 pg/mL.
Click to get more Data / Case study about the product.
Target/Biomarker information
Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. Low plasma Aβ42/40 was associated with more pronounced decline in cognitive function (measured by multiple outcomes) over time. Findings suggest that plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an alternative to more complex and expensive measures, such as positron emission tomography imaging or cerebrospinal fluid measurement.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.